SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
2.220
-0.220 (-9.02%)
At close: Nov 26, 2025, 4:00 PM EST
2.171
-0.049 (-2.21%)
After-hours: Nov 26, 2025, 7:59 PM EST
SciSparc Revenue
SciSparc had revenue of $1.31M in the twelve months ending September 30, 2025, down -14.44% year-over-year. In the year 2024, SciSparc had annual revenue of $1.31M, down -54.64%.
Revenue (ttm)
$1.31M
Revenue Growth
-14.44%
P/S Ratio
2.76
Revenue / Employee
$653,000
Employees
2
Market Cap
3.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.31M | -1.57M | -54.64% |
| Dec 31, 2023 | 2.88M | 1.53M | 113.73% |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SPRC News
- 1 day ago - SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems - GlobeNewsWire
- 7 days ago - SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - GlobeNewsWire
- 8 days ago - Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - TheNewswire
- 4 weeks ago - SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio - GlobeNewsWire
- 5 weeks ago - SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire
- 5 weeks ago - SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery - GlobeNewsWire
- 5 weeks ago - Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc. - TheNewswire
- 5 weeks ago - SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders - GlobeNewsWire